Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have changed the therapeutic paradigm of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative advanced breast cancer (ABC). The gene discussed is NR4A1; the disease is breast cancer.